Biotech Startups

Nuage Therapeutics develops drug discovery technologies for disordered proteins, focusing on precision treatments for aggressive cancers with limited therapeutic options. The company targets disease-causing protein targets rooted in human biology.

3 investors

Nucleix is a healthcare company developing diagnostic technology based on DNA/nucleic acid analysis for cancer detection. It serves the medical diagnostics and biotechnology market.

3 investors

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

3 investors

Nuclera provides multiplex protein screening technology for life science researchers, enabling faster access to and testing of proteins for drug discovery and development. The company serves protein scientists and research teams accelerating breakthroughs in structural biology and functional studies.

3 investors

Nuevocor is a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases. The company leverages innovative cell biology and gene therapy technologies to address genetic and acquired cardiac conditions.

3 investors

Nulixir appears to be a beverage or wellness product company that formulates drinks with herbal extracts, amino acids, and vitamins. The page shows a board of advisors section featuring Gerry, an experienced executive with extensive background in consumer products, manufacturing, and beverage industry turnarounds.

3 investors

Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.

3 investors

Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.

3 investors

RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.

3 investors

Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings. The company focuses on treating the interconnection between heart and kidney function to improve patient outcomes and accelerate recovery.

3 investors

Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function. It targets both TEER-suitable patients and those with limited existing treatment options in the cardiology/medical device field.

3 investors

NZeno develops porcine (pig) cell-based therapeutics and xenotransplantation technologies, building on work in encapsulated cell therapies and breeding pigs certified as tissue sources for human transplantation. The company operates in the biotechnology and regenerative medicine field.

3 investors

OCON Medical develops intrauterine devices for gynecological conditions, including non-hormonal contraception and treatments for abnormal uterine bleeding. The company's products serve women seeking alternatives to hormonal methods and surgical interventions.

3 investors

Mooji Meats develops a proprietary Cross-Fiber Assembly platform that adds meaty whole-cut textures to plant-based and real-meat proteins at scale, with a flagship line of plant-based filet mignons. It sells its Offbeast products direct to home cooks and to restaurants through foodservice channels.

3 investors

Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.

3 investors

OMTX develops machine learning tools and datasets for drug discovery, helping researchers globally identify new therapeutic mechanisms of action and accelerate the development of medicines.

3 investors

Omniox is an IND-stage biotechnology company developing OMX oxygen-delivery vehicles based on its H-NOX platform technology to treat medical conditions where tissue hypoxia drives disease. The therapies target difficult clinical problems in which low oxygen levels play a central role in worsening patient outcomes.

3 investors

Omniscope develops diagnostics and therapeutics technology based on the convergence of AI and immunology, aiming to interpret immune system data to generate therapeutics, develop diagnostics, and monitor patients. Founded in 2020, the company applies machine learning to immunology with a focus on health equity.

3 investors

ONASPORT is a wearable device that monitors athletic performance through non-invasive analysis of sweat-based biomarkers including lactate, sodium, dehydration, and electrolyte loss. The system connects via Bluetooth to a cloud-based app for iOS and Android, enabling athletes to track training data and manage team performance.

3 investors

Oncoinvent is a biotechnology company focused on drug development and commercialization in the pharmaceutical sector. The company is led by executives with extensive experience in biotech management, clinical programs, and global pharmaceutical commercialization.

3 investors

Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine). The company targets an orphan drug indication with clinical development underway.

3 investors

OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.

3 investors

OnePot is a tool for synthesizing molecules, with end-to-end encryption of users' molecular structures. It appears aimed at chemistry and drug discovery users who require confidentiality of their chemical data.

3 investors

OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.

3 investors